Unaudited Financial Results for the quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pharmaids Pharmaceuticals reported a sharply wider loss in Q1 FY26 despite strong revenue growth. On a consolidated basis, revenue from operations rose to Rs 666.36 lakhs from Rs 473.07 lakhs in the year-ago quarter, a growth of about 41%. However, total expenses surged to Rs 1,387.49 lakhs (from Rs 896.50 lakhs), driven by higher employee costs, finance costs, and other expenses. Consolidated net loss widened to Rs 531.53 lakhs (from Rs 312.45 lakhs), and standalone net loss ballooned to Rs 436.30 lakhs (from Rs 162.34 lakhs). The auditor issued a clean limited review report with an Emphasis of Matter on the post-quarter disinvestment of the company's 66.50% stake in Anugraha Chemicals, subject to shareholder approval via postal ballot. The company is a contract research and manufacturing services (CRAMS) player, and losses continue to erode its equity base (other equity of Rs 2,405.25 lakhs on consolidated books).
Losses are widening and shareholders' equity is being eroded, which is a negative signal for the stock despite revenue growth. The pending sale of the Anugraha Chemicals stake may bring in cash but also reduces the consolidated entity's footprint; watch the postal ballot outcome on August 14, 2025.